Valentino Parravicini

Valentino Parravicini is a seasoned scientific leader with extensive experience in drug development and immunology. Currently serving as the Chief Scientific Officer at Axelyf since January 2024, Valentino is responsible for overseeing drug development initiatives focused on autoimmunity and inflammation. Additionally, Valentino holds the position of Chief Scientific Officer at Oxford Cannabinoid Technologies, directing efforts to harness cannabinoids for unmet medical needs since July 2020. Prior experience includes roles as the Translational Science Group Lead at GammaDelta Therapeutics, where Valentino managed strategic non-clinical safety and efficacy studies, and as a Senior Scientist at Kesios Therapeutics, focusing on oncology asset validation and preclinical assessments. Valentino's early career includes significant contributions as an Investigator at GSK, leading research projects in epigenetics related to immune-inflammatory disorders and oncology.